Published on 22/12/2025
Understanding Sponsor and Site Responsibilities During Inspections
Shared Accountability in Regulatory Inspections
Regulatory inspections, whether routine or for-cause, assess the integrity, conduct, and regulatory compliance of clinical trials. Both sponsors and clinical sites play critical and often overlapping roles during these inspections. Agencies such as the FDA, EMA, MHRA, and Health Canada hold sponsors accountable for oversight, while simultaneously evaluating the site’s adherence to protocol and GCP principles.
A well-coordinated inspection approach between sponsor and site can mitigate risks, prevent miscommunication, and ensure the inspection progresses efficiently. In this guide, we break down the responsibilities of each party and explore how collaboration contributes to successful inspection outcomes.
Site Responsibilities During Inspection
Clinical sites are directly responsible for the execution of the protocol, subject safety, and source data collection. During an inspection, their preparedness and transparency are scrutinized. Key site responsibilities include:
- Investigator Presence: The Principal Investigator (PI) must be available during the inspection to answer protocol-related and subject-specific questions.
- Informed Consent Documentation: Sites must provide complete ICF logs, including versions, approvals, and signed forms.
- Source Data Verification: Investigators and study coordinators should ensure subject charts, lab results, and visit documentation are aligned with Case Report Forms (CRFs).
- Training Records:
Sites are expected to facilitate prompt access to all requested documentation and systems, often using secure electronic access or paper backups.
Sponsor Responsibilities During Inspection
Sponsors hold overarching responsibility for trial design, monitoring, data oversight, and GCP compliance across all participating sites. During an inspection, they serve both a direct and supportive role. Key sponsor tasks include:
- Trial Master File (TMF) Preparation: Ensure that the eTMF is inspection-ready, with indexed and version-controlled documents available on request.
- CRA Inspection Support: Clinical Research Associates (CRAs) familiar with the site and study should be available to assist with monitoring-related questions.
- System Access Management: Provide login access to EDC, CTMS, and ePRO systems with role-based permissions and audit trails.
- Central Safety Reporting: Sponsors should be ready to explain SAE reporting workflows, reconciliation methods, and expedited reporting compliance.
- Vendor Oversight Documentation: Share contracts, vendor qualification audits, and oversight reports for external parties like central labs or imaging vendors.
Establishing the Inspection Leadership Team
Both sponsor and site should identify an inspection coordination team in advance. Typical roles include:
| Role | Responsibility | Entity |
|---|---|---|
| Inspection Host | Greets inspector, manages logistics, and coordinates sessions | Site and/or Sponsor |
| Subject Matter Expert (SME) | Answers questions related to specific systems or data | Sponsor or Site as needed |
| Document Retriever | Responsible for locating and presenting requested documents | Site staff or Sponsor TMF coordinator |
| Scribe | Records inspector questions, site responses, and document access | Designated Sponsor or Site QA staff |
Communication Protocol During Inspections
Clear, respectful, and factual communication is essential during inspections. Sponsors and sites should adhere to the following:
- Never speculate or guess — defer to SME if needed
- Document every interaction and question-answer exchange
- Designate a single spokesperson per entity (site and sponsor)
- Respond only to what is asked — avoid oversharing
Daily debrief meetings between sponsor, site, and inspection staff are essential to align on findings, prepare follow-up documentation, and address discrepancies early.
Collaborative Inspection Tools and Checklists
Many sponsors now maintain shared inspection readiness portals or cloud folders with the following:
- Preloaded SOPs and policy documents
- Completed monitoring visit reports and follow-ups
- CAPA log status for recent audits
- Protocol deviation logs and resolutions
- IRB/EC correspondence templates
Review public resources such as the Health Canada Clinical Trials Database to understand which trials are being audited and assess inspection trends.
Conclusion: A Unified Approach Is Key
Inspections test more than documentation — they assess the culture of compliance and the collaboration between all stakeholders. By understanding the roles of sponsors and sites, assigning clear responsibilities, and rehearsing coordination protocols, clinical trial teams can build confidence and resilience. Unified readiness is the cornerstone of a successful inspection outcome.